

# **ORBIT PHARMA LIMITED**

**Company Registration Number:  
13918951 (England and Wales)**

**Unaudited abridged accounts for the year ended 28 February 2023**

**Period of accounts**

**Start date: 16 February 2022**

**End date: 28 February 2023**

# **ORBIT PHARMA LIMITED**

## **Contents of the Financial Statements for the Period Ended 28 February 2023**

Balance sheet

Notes

# ORBIT PHARMA LIMITED

## Balance sheet

As at 28 February 2023

	<i>Notes</i>	<i>2023</i>
		£
<b>Fixed assets</b>		
Intangible assets:	3	557,187
Tangible assets:	4	9,679
Investments:	5	102
<b>Total fixed assets:</b>		<u>566,968</u>
<b>Current assets</b>		
Debtors:		34,950
Cash at bank and in hand:		13,276
<b>Total current assets:</b>		<u>48,226</u>
Creditors: amounts falling due within one year:		(598,955)
<b>Net current assets (liabilities):</b>		<u>(550,729)</u>
Total assets less current liabilities:		16,239
<b>Total net assets (liabilities):</b>		<u>16,239</u>
<b>Capital and reserves</b>		
Called up share capital:		100
Profit and loss account:		16,139
<b>Shareholders funds:</b>		<u>16,239</u>

The notes form part of these financial statements

# **ORBIT PHARMA LIMITED**

## **Balance sheet statements**

For the year ending 28 February 2023 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company's profit & loss account.

**This report was approved by the board of directors on 13 February 2024  
and signed on behalf of the board by:**

Name: Hetalbaben Patel  
Status: Director

The notes form part of these financial statements

# **ORBIT PHARMA LIMITED**

## **Notes to the Financial Statements**

**for the Period Ended 28 February 2023**

### **1. Accounting policies**

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

# **ORBIT PHARMA LIMITED**

## **Notes to the Financial Statements for the Period Ended 28 February 2023**

### **2. Employees**

*2023*

**Average number of employees during the period**

**2**

# ORBIT PHARMA LIMITED

## Notes to the Financial Statements for the Period Ended 28 February 2023

### 3. Intangible Assets

	Total
<b>Cost</b>	£
Additions	557,187
At 28 February 2023	<u>557,187</u>
<b>Amortisation</b>	
Charge for year	0
At 28 February 2023	<u>0</u>
<b>Net book value</b>	
At 28 February 2023	<u><u>557,187</u></u>

# ORBIT PHARMA LIMITED

## Notes to the Financial Statements for the Period Ended 28 February 2023

### 4. Tangible Assets

	Total
<b>Cost</b>	£
Additions	9,885
At 28 February 2023	<u>9,885</u>
<b>Depreciation</b>	
Charge for year	206
At 28 February 2023	<u>206</u>
<b>Net book value</b>	
At 28 February 2023	<u><u>9,679</u></u>



# **ORBIT PHARMA LIMITED**

## **Notes to the Financial Statements for the Period Ended 28 February 2023**

### **5. Fixed investments**

Fixed asset investments are stated at cost less provision for any permanent diminution in value.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.